TrkA oncogenes are activated and play significant roles in many human cancers, and cancers driven by TrkA oncogenes exhibit profound, long-lived responses to novel clinically approved Trk inhibitors, such as Larotrectinib [16–18], suggesting that TrkA-targeted therapy may have a place in the treatment of MCC. Here, NTRK1 is linked to cancer.